Abstract:Both α-Synuclein (αSyn) accumulation and mitochondrial dysfunction have been implicated in the pathology of Parkinson’s disease (PD). Although studies suggest that αSyn and its missense mutant, A53T, preferentially accumulate in the mitochondria, the mechanisms by which αSyn and mitochondrial proteins regulate each other to trigger mitochondrial and neuronal toxicity are poorly understood. ATP-dependent Clp protease (ClpP), a mitochondrial matrix protease, plays an important role in regulating mitochondrial protein turnover and bioenergetics activity. Here, we show that the protein level of ClpP is selectively decreased in αSyn-expressing cell culture and neurons derived from iPS cells of PD patient carrying αSyn A53T mutant, and in dopaminergic (DA) neurons of αSyn A53T mice and PD patient postmortem brains. Deficiency in ClpP induces an overload of mitochondrial misfolded/unfolded proteins, suppresses mitochondrial respiratory activity, increases mitochondrial oxidative damage and causes cell death. Overexpression of ClpP reduces αSyn-induced mitochondrial oxidative stress through enhancing the level of Superoxide Dismutase-2 (SOD2), and suppresses the accumulation of αSyn S129 phosphorylation and promotes neuronal morphology in neurons derived from PD patient iPS cells carrying αSyn A53T mutant. Moreover, we find that αSyn WT and A53T mutant interact with ClpP and suppress its peptidase activity. The binding of αSyn to ClpP further promotes a distribution of ClpP from soluble to insoluble cellular fraction in vitro and in vivo, leading to reduced solubility of ClpP. Compensating for the loss of ClpP in the substantia nigra of αSyn A53T mice by viral expression of ClpP suppresses mitochondrial oxidative damage, and reduces αSyn pathology and behavioral deficits of mice. Our findings provide novel insights into the mechanism underlying αSyn-induced neuronal pathology, and they suggest that ClpP might be a useful therapeutic target for PD and other synucleinopathies.

Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity

Cathepsin L prevents the accumulation of alpha‐synuclein fibrils in the cell

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Alpha-synuclein preformed fibril-induced aggregation and dopaminergic cell death in cathepsin D overexpression and ZKSCAN3 knockout mice

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies

Cathepsin D overexpression in the nervous system rescues lethality and A β 42 accumulation of cathepsin D systemic knockout in vivo

Alteration of dynein function affects α-synuclein degradation via the autophagosome-lysosome pathway.

Microglial LRRK2-mediated NFATc1 attenuates α-synuclein immunotoxicity in association with CX3CR1-induced migration and the lysosome-initiated degradation

Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity

Analysis of Α-Synuclein Species Enriched from Cerebral Cortex of Humans with Sporadic Dementia with Lewy Bodies.

The role of polo-like kinases 2 in the proteasomal and lysosomal degradation of alpha-synuclein in neurons

α-Synuclein amyloid fibril directly binds to LC3B and suppresses SQSTM1/p62-mediated selective autophagy

Dopamine Prevents Lipid Peroxidation-Induced Accumulation of Toxic Α-Synuclein Oligomers by Preserving Autophagy-Lysosomal Function

Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.

Effects of Lanthionine Ketimine-5-Ethyl Ester on the α-Synucleinopathy Mouse Model

Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant Α-Synuclein

α-Synuclein at the Presynaptic Axon Terminal as a Double-Edged Sword

Α‐synuclein Stimulation of Monoamine Oxidase‐b and Legumain Protease Mediates the Pathology of Parkinson's Disease

USP19 deubiquitinase inactivation regulates α-synuclein ubiquitination and inhibits accumulation of Lewy body-like aggregates in mice

Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy

CSPα reduces aggregates and rescues striatal dopamine release in α-synuclein transgenic mice